Contributors |
|
xv | |
Preface |
|
xxi | |
Part I Molecular and cellular aspects |
|
|
1 KCNQ/Kv7 channels as therapeutic target to treat neuropathic pain |
|
|
|
|
|
|
3 | (1) |
|
KCNQ/Kv7 channel family members |
|
|
3 | (1) |
|
KCNQ proteins and function |
|
|
3 | (1) |
|
KCNQ channel compositions |
|
|
4 | (1) |
|
KCNQ channels in primary sensory neurons and their contribution to neuropathic pain |
|
|
5 | (2) |
|
Primary sensory neurons and neuropathic pain |
|
|
5 | (1) |
|
KCNQ channels in primary sensory neurons |
|
|
6 | (1) |
|
Plasticity of KCNQ channels and their contribution to neuropathic pain |
|
|
6 | (1) |
|
KCNQ channels as therapeutic target to treat neuropathic pain |
|
|
7 | (1) |
|
KCNQ channels as therapeutic target to treat established pain |
|
|
7 | (1) |
|
KCNQ channels as therapeutic target to prevent the development of neuropathic pain |
|
|
8 | (1) |
|
|
8 | (1) |
|
Applications to other areas |
|
|
9 | (1) |
|
|
10 | (1) |
|
|
10 | (1) |
|
Key facts of KCNQ/Kv7 channels and neuropathic pain |
|
|
10 | (1) |
|
|
10 | (1) |
|
|
10 | (3) |
|
2 A new mutation in NTRK1 gene is associated with congenital insensitivity to pain without anhidrosis |
|
|
|
|
|
|
|
|
13 | (6) |
|
The applications to other areas |
|
|
19 | (1) |
|
|
19 | (1) |
|
|
20 | (1) |
|
|
20 | (1) |
|
|
20 | (3) |
|
3 Prdm12, a key transcriptional regulator of the nociceptive lineage |
|
|
|
|
|
|
|
23 | (1) |
|
|
24 | (1) |
|
Mutations in PRDM12 cause CIP and midface toddler excoriation syndrome |
|
|
25 | (1) |
|
Prdm12 is selectively expressed in developing somatosensory ganglia in the nociceptive lineage |
|
|
26 | (1) |
|
Prdm12 is essential for the emergence of the entire nociceptive lineage |
|
|
26 | (1) |
|
How does Prdm12 function in the specification and maturation of nociceptive neurons? |
|
|
26 | (1) |
|
Does Prdm12 play a role in mature nociceptors? |
|
|
27 | (1) |
|
Applications to other areas |
|
|
28 | (1) |
|
|
28 | (1) |
|
|
29 | (1) |
|
Key facts showing the importance of Prdm12 in nociceptors |
|
|
29 | (1) |
|
|
29 | (1) |
|
|
29 | (4) |
|
4 Genetics of chronic widespread musculoskeletal pain |
|
|
|
Maria Jesus Alvarez-Cubero |
|
|
|
Veronica Arenas-Rodriguez |
|
|
|
Luis Javier Martinez-Gonzalez |
|
|
|
33 | (1) |
|
Heritability of chronic widespread musculoskeletal pain |
|
|
34 | (1) |
|
Candidate gene studies in chronic widespread musculoskeletal pain |
|
|
34 | (5) |
|
|
35 | (3) |
|
Association genotype-phenotype |
|
|
38 | (1) |
|
SNPs that has been studied in only one analysis in fibromyalgia |
|
|
38 | (1) |
|
|
39 | (1) |
|
Interactions (gene-gene and gene-environment) |
|
|
39 | (1) |
|
Future perspectives (mainly, research agenda) |
|
|
40 | (1) |
|
Applications to other areas |
|
|
41 | (1) |
|
|
41 | (1) |
|
|
41 | (1) |
|
|
41 | (1) |
|
|
41 | (4) |
|
5 Fentanyl: Polymorphisms, and adverse events |
|
|
|
|
|
Opioid fentanyl use in pain management |
|
|
45 | (4) |
|
|
46 | (1) |
|
|
47 | (1) |
|
Fentanyl misuse and abuse |
|
|
48 | (1) |
|
Potential pharmacogenetics markers in fentanyl pain management |
|
|
49 | (3) |
|
|
50 | (2) |
|
Barriers to implementation |
|
|
52 | (1) |
|
|
53 | (1) |
|
Applications to other areas |
|
|
53 | (1) |
|
|
53 | (1) |
|
|
53 | (1) |
|
|
54 | (1) |
|
|
54 | (1) |
|
|
54 | (3) |
|
6 Propofol anesthesia and molecular changes in the brain |
|
|
|
|
|
|
|
57 | (1) |
|
|
58 | (1) |
|
Neural and molecular targets of propofol |
|
|
58 | (3) |
|
Propofol-induced brain molecular changes during postanesthesia period |
|
|
59 | (1) |
|
Molecular changes that reflect alterations in neuronal activity at the peak of brain growth spurt |
|
|
59 | (1) |
|
Age-dependent peculiarities in the expression of neurotrophins and their downstream signaling pathways |
|
|
59 | (1) |
|
Neuronal activity and synaptic plasticity |
|
|
60 | (1) |
|
Molecular autograph of longer exposures to propofol at the peak of the brain growth spurt |
|
|
61 | (1) |
|
Propofol and age-related brain pathology |
|
|
61 | (1) |
|
Applications to other areas |
|
|
61 | (1) |
|
|
62 | (1) |
|
|
62 | (1) |
|
Key fads of propofol anesthesia and molecular changes in the brain |
|
|
63 | (1) |
|
|
64 | (1) |
|
|
64 | (3) |
|
7 Protein kinase G is a molecular switch for pain |
|
|
|
|
|
|
67 | (1) |
|
Pain is perceived via inputs from nociceptive circuits that are adaptive |
|
|
67 | (2) |
|
|
67 | (1) |
|
The acute perception of pain |
|
|
68 | (1) |
|
The prolonged perception of pain |
|
|
68 | (1) |
|
|
68 | (1) |
|
|
69 | (3) |
|
Distinction between persistent and chronic pain |
|
|
70 | (1) |
|
LTH is induced by protein kinase G, a positive injury signal in nociceptive neurons |
|
|
70 | (1) |
|
PKG-1α is a nociceptive positive injury signal for LTH in rats |
|
|
70 | (1) |
|
Persistent activity of PKG-la in sensory neurons after nerve injury in rats |
|
|
71 | (1) |
|
Development of a novel potent PKG inhibitor |
|
|
72 | (3) |
|
N46 effectively alleviates chronic osteoarthritic and inflammation-induced pain |
|
|
74 | (1) |
|
Side effects and the fate of N46 in vivo |
|
|
74 | (1) |
|
|
75 | (1) |
|
Applications to other areas |
|
|
75 | (1) |
|
|
75 | (1) |
|
|
75 | (1) |
|
|
75 | (1) |
|
|
75 | (1) |
|
|
76 | (3) |
|
8 Adrenergic agonists and antagonists enhance opioid receptor activity |
|
|
|
|
|
79 | (1) |
|
Anatomical and cellular codistribution of opioid and adrenergic functions |
|
|
79 | (1) |
|
Mechanisms of adrenergic receptor-opioid receptor cross-talk |
|
|
80 | (1) |
|
Opioids bind to adrenergic receptors |
|
|
80 | (1) |
|
Adrenergic compounds bind to opioid receptors |
|
|
80 | (1) |
|
Opioid receptor-adrenergic receptor heterodimerization |
|
|
81 | (1) |
|
A model of adrenoceptor-opioid receptor cross-talk |
|
|
81 | (3) |
|
Synergistic effects of adrenergic-opioid receptor cross-talk in the treatment of pain |
|
|
84 | (1) |
|
Prevention of desensitization and mutual resensitization of opioid and adrenergic receptor function by each other's ligands |
|
|
84 | (1) |
|
Applications to other areas: Local anesthetic enhancement and opioid sparing uses |
|
|
85 | (1) |
|
Other agents of interest: Ascorbic acid, tramadol and tapentadol, and ketamine |
|
|
85 | (1) |
|
|
86 | (1) |
|
|
86 | (1) |
|
|
86 | (1) |
|
|
86 | (5) |
|
9 Inflammatory and neuropathic pain impact on the opioid function in the mesocorticolimbic system |
|
|
|
|
|
|
|
|
|
91 | (1) |
|
A short introduction to the opioid receptors |
|
|
92 | (1) |
|
The endogenous opioid system: A key component of analgesia, reward, and aversion |
|
|
92 | (1) |
|
Chronic pain alters brain function and connectivity recruiting motivational and emotional regions |
|
|
92 | (2) |
|
PET imaging confirms pain-induced alterations of ORs in the MCLS during pain |
|
|
94 | (1) |
|
Preclinical studies show altered MOR density or function derived from the presence of pain |
|
|
94 | (2) |
|
Animal models of pain showed altered DA-related behaviors derived from the pharmacological activation of MORs |
|
|
96 | (2) |
|
Inflammatory pain promotes increased opioid self-administration |
|
|
98 | (1) |
|
Dynorfin/KOR system (Dyn/KOR) of the MCLS: A new key player in pain field |
|
|
98 | (1) |
|
Applications to other areas |
|
|
98 | (2) |
|
|
100 | (1) |
|
Key facts of pain-induced changes in OR function |
|
|
100 | (1) |
|
|
100 | (1) |
|
|
100 | (4) |
|
10 Clinacanthus nutans L., analgesia, and the 1-arginine/nitric oxide-mediated/cyclic-guanosine monophosphate-independent pathway |
|
|
|
|
|
104 | (1) |
|
Herbal remedies for the treatment of pain |
|
|
104 | (1) |
|
|
104 | (1) |
|
Report on findings related to the antinociceptive activity of C. nutans |
|
|
104 | (2) |
|
Antinociceptive profile of MCNL and the possible mechanisms of antinociception |
|
|
104 | (2) |
|
Antinociceptive profile of PEP and the possible mechanisms of antinociception |
|
|
106 | (1) |
|
Phytoconstituents of MCNL and PEP |
|
|
107 | (1) |
|
Conclusion based on the reported antinociceptive activity of MCNL and PEP |
|
|
107 | (1) |
|
Involvement of peripheral and central antinociceptive mechanisms |
|
|
108 | (1) |
|
Involvement of various mechanisms of antinociception |
|
|
109 | (1) |
|
Role of general opioidergic system |
|
|
109 | (1) |
|
Involvement of specific opioidergic system subtypes |
|
|
110 | (1) |
|
Role of nonopioidergic systems |
|
|
110 | (1) |
|
Involvement of transient receptor potential vanilloid type 1 (TRPV1) receptors, glutamatergic system, protein kinase C (PKC)-mediated pathway, and bradykininergic system |
|
|
110 | (1) |
|
Involvement of α2-adrenergic, β-adrenergic, adenosinergic, dopaminergic, or muscarinic cholinergic receptor systems |
|
|
110 | (1) |
|
Involvement of various types of K+ channels |
|
|
111 | (1) |
|
Role of NO-mediated pathways |
|
|
111 | (1) |
|
Applications to other areas |
|
|
111 | (1) |
|
|
112 | (1) |
|
|
112 | (1) |
|
|
113 | (1) |
|
|
113 | (1) |
|
|
113 | (1) |
|
|
113 | (4) |
|
11 The orally bioavailable imidazodiazepine, KRM-II-81, is a novel potentiator of α2/3-containing GABAA receptors with analgesic efficacy |
|
|
|
|
|
|
|
|
|
|
|
117 | (1) |
|
|
117 | (1) |
|
GABAA receptor potentiating benzodiazepines and pain |
|
|
118 | (1) |
|
Alpha 2/3-containing GABAA receptors |
|
|
118 | (2) |
|
|
120 | (1) |
|
|
120 | (2) |
|
|
122 | (1) |
|
Applications to other therapeutic areas |
|
|
123 | (1) |
|
|
123 | (1) |
|
|
124 | (1) |
|
|
124 | (1) |
|
|
124 | (1) |
|
|
124 | (1) |
|
|
124 | (1) |
|
|
124 | (3) |
|
|
127 | (2) |
|
12 Extrasynaptic α5GABAA receptors and their role in nociception and pathological pain |
|
|
|
|
Yarim E. De la Luz-Cuellar |
|
|
Luis Eduardo Hernandez-Reyes |
|
|
|
|
|
|
|
|
129 | (1) |
|
|
130 | (1) |
|
Expression of α5GABAA receptors at spinal cord and DRG |
|
|
130 | (1) |
|
GABAergic tonic current in the spinal cord |
|
|
130 | (2) |
|
GABAergic tonic current in spinal cord in mammals |
|
|
132 | (1) |
|
Extrasynaptic α5GABAA receptors in the rate-dependent depression (RDD) of the Hoffmann reflex (HR) |
|
|
132 | (1) |
|
Function of extrasynaptic α5GABAA receptors in primary afferent fibers |
|
|
133 | (1) |
|
Extrasynaptic spinal a5GABAA receptors in pain |
|
|
133 | (1) |
|
Extrasynaptic α5GABAA receptors regulation |
|
|
133 | (1) |
|
Applications to other areas |
|
|
133 | (2) |
|
|
135 | (1) |
|
|
135 | (1) |
|
Key facts on α5GABAA receptors in pain |
|
|
135 | (1) |
|
|
135 | (1) |
|
|
136 | (1) |
|
|
136 | (3) |
|
13 ATP-sensitive potassium channels in pain and analgesia |
|
|
|
|
Debora de Oliveira Santos |
|
|
Celina Monteiro da Cruz Lotufo |
|
|
ATP-sensitive potassium channels (Katp) |
|
|
139 | (2) |
|
Possible role for Katp channels in primary nociceptive neurons during hyperglycemia |
|
|
141 | (2) |
|
Katp involvement in the mechanisms of analgesic substances |
|
|
143 | (3) |
|
Application to other areas |
|
|
146 | (1) |
|
|
146 | (1) |
|
|
146 | (1) |
|
|
146 | (1) |
|
|
147 | (1) |
|
|
147 | (4) |
|
14 Astrocyte-neuron lactate shuttle and pain |
|
|
|
|
|
|
151 | (3) |
|
Applications to other areas |
|
|
154 | (1) |
|
|
154 | (2) |
|
|
156 | (1) |
|
|
157 | (1) |
|
Key facts of astrocyte-neuron lactate shuttle |
|
|
157 | (1) |
|
|
157 | (1) |
|
|
157 | (4) |
|
15 Nociception and sweet solutions: Applications to inflammatory pain |
|
|
|
|
|
|
|
161 | (1) |
|
Inflammatory pain pathways |
|
|
162 | (1) |
|
Pain behaviors and assessment |
|
|
163 | (1) |
|
Use of sweet solutions for inflammatory pain |
|
|
163 | (1) |
|
Mechanisms of sweet solutions for inflammatory pain |
|
|
164 | (1) |
|
Sweet tasting solutions used for analgesia |
|
|
164 | (1) |
|
|
164 | (1) |
|
Importance of treatment of neonatal pain |
|
|
165 | (1) |
|
Applications to other areas |
|
|
165 | (1) |
|
|
165 | (1) |
|
|
166 | (1) |
|
|
166 | (1) |
|
|
166 | (1) |
|
|
166 | (1) |
|
|
166 | (1) |
|
|
167 | (5) |
|
16 Interlinking interleukin-33 (IL-33), neuroinflammation and neuropathic pain |
|
|
|
|
Fernanda Soares Rasquel-Oliveira |
|
|
|
|
Thacyana Teixeira Carvalho |
|
|
|
|
|
|
|
172 | (1) |
|
Neuropathic pain and glial cells |
|
|
173 | (1) |
|
|
174 | (2) |
|
|
174 | (1) |
|
|
175 | (1) |
|
|
176 | (1) |
|
Applications to other areas |
|
|
176 | (1) |
|
|
177 | (1) |
|
|
177 | (1) |
|
Key facts of IL-33 in neuropathic pain |
|
|
177 | (1) |
|
|
178 | (1) |
|
|
178 | (1) |
|
|
179 | (5) |
|
17 Neurons of the parabrachial nucleus, nociceptive input, and pain pathways |
|
|
|
|
|
|
|
184 | (1) |
|
|
185 | (1) |
|
Afferent pain transmitting pathways to the LPB |
|
|
186 | (1) |
|
Nociceptive neurons in the LPB and their aversive pathway to amygdala and bed nucleus of the stria terminalis (BNST) |
|
|
186 | (1) |
|
CGRP-positive neurons in the PBeI |
|
|
187 | (1) |
|
Nociceptive neurons in the LPB and their autonomic connection with the hypothalamus |
|
|
187 | (1) |
|
Pain-modulating pathways from the LPB |
|
|
187 | (1) |
|
|
188 | (1) |
|
Applications to other areas |
|
|
188 | (1) |
|
|
189 | (1) |
|
|
189 | (1) |
|
|
189 | (4) |
|
18 Anterior cingulate cortex, pain perception, and pathological neuronal plasticity during chronic pain |
|
|
|
|
|
|
|
193 | (1) |
|
ACC is a critical hub linking neuronal circuits for nociception and emotion |
|
|
194 | (1) |
|
ACC activation is associated with the affective component of pain |
|
|
194 | (1) |
|
ACC neuronal activity mediates pain-induced negative affect |
|
|
195 | (1) |
|
Nociception-related neurons in the ACC |
|
|
196 | (1) |
|
Distinct cortical representation of acute and chronic pain |
|
|
197 | (1) |
|
Pathological neuronal plasticity in the ACC associated to chronic pain |
|
|
198 | (1) |
|
Applications to other areas |
|
|
198 | (1) |
|
Interfering with pathological cortical plasticity as a therapeutic approach for chronic pain |
|
|
198 | (1) |
|
|
199 | (1) |
|
Anterior insular cortex and pain affect |
|
|
199 | (1) |
|
|
200 | (1) |
|
|
200 | (1) |
|
Key facts of neuronal plasticity in health and disease |
|
|
200 | (1) |
|
|
200 | (1) |
|
|
201 | (2) |
|
19 Sleep deprivation, headache, and Fos immunohistochemistry |
|
|
|
|
|
|
203 | (1) |
|
Pain, headache, and sleep deprivation |
|
|
203 | (1) |
|
The pathophysiologic relationship between sleep deprivation and headache |
|
|
204 | (1) |
|
Modulation of headache and sleep-wake cycles |
|
|
204 | (1) |
|
|
204 | (1) |
|
|
205 | (1) |
|
Pharmacologic relationships between headache and sleep |
|
|
205 | (2) |
|
|
205 | (1) |
|
|
206 | (1) |
|
|
207 | (1) |
|
Pituitary adenylate cyclase activating peptide (PACAP) |
|
|
207 | (1) |
|
Experimental research to examine headache and sleep deprivation |
|
|
207 | (4) |
|
|
207 | (1) |
|
Animal model of sleep deprivation |
|
|
208 | (2) |
|
Animal model of headache (activation of the trigeminovascular system) |
|
|
210 | (1) |
|
Experimental studies of sleep deprivation and headache pain |
|
|
211 | (2) |
|
Applications to other areas |
|
|
213 | (1) |
|
|
213 | (1) |
|
|
213 | (1) |
|
Key facts of sleep deprivation and headache |
|
|
213 | (1) |
|
|
213 | (1) |
|
|
213 | (5) |
|
20 Antinociceptive glucagon-like peptides |
|
|
|
|
Introduction to the glucagon-like peptides |
|
|
218 | (1) |
|
Applications to other areas |
|
|
218 | (1) |
|
Glucagon-like peptide-1 and its analogs |
|
|
219 | (2) |
|
|
221 | (1) |
|
|
222 | (1) |
|
|
223 | (1) |
|
Key facts of glucagon-like peptides |
|
|
223 | (1) |
|
|
223 | (1) |
|
|
223 | (5) |
|
21 Pain transmission and peripheral group III metabotropic glutamate receptors (mGluRs) |
|
|
|
|
|
|
228 | (1) |
|
Glutamate metabolism in peripheral nervous system |
|
|
228 | (1) |
|
Glutamate release and pain |
|
|
228 | (1) |
|
Glutamate receptor signaling: iGluR and mGluR |
|
|
229 | (1) |
|
Localization of peripheral group III mGluR |
|
|
229 | (1) |
|
Negative modulation of pain transmission |
|
|
230 | (3) |
|
Group III mGluRs in non-neuronal glial cells |
|
|
233 | (1) |
|
Applications to other areas |
|
|
234 | (1) |
|
|
235 | (1) |
|
|
235 | (1) |
|
Key facts of activity-dependent inhibition |
|
|
235 | (1) |
|
|
235 | (1) |
|
|
236 | (3) |
|
22 TRPM8 receptor and menthol in pain management |
|
|
|
|
|
|
239 | (1) |
|
Transient receptor potential channels |
|
|
240 | (1) |
|
|
240 | (1) |
|
|
241 | (3) |
|
Posttraumatic and postoperative pain |
|
|
244 | (1) |
|
|
244 | (1) |
|
|
245 | (1) |
|
|
246 | (1) |
|
Pregnant and lactating women |
|
|
246 | (1) |
|
|
247 | (1) |
|
|
247 | (1) |
|
|
247 | (1) |
|
|
247 | (1) |
|
Applications to other areas |
|
|
248 | (1) |
|
|
248 | (1) |
|
Key facts of TRPM8 receptor and menthol |
|
|
249 | (1) |
|
|
249 | (1) |
|
|
249 | (2) |
|
|
251 | (4) |
Part II Physiology, imaging and physical recordings |
|
|
23 Anesthetic and proconvulsant effects of ketamine on EEG |
|
|
|
|
|
|
255 | (1) |
|
Ketamine effects as anesthetic |
|
|
256 | (1) |
|
Ketamine effects as proconvulsant |
|
|
257 | (1) |
|
EEG analysis of ketamine effects |
|
|
257 | (1) |
|
Scalp vs intracranial EEG effects of ketamine in nonhuman primate model of an idiopathic generalized epilepsy |
|
|
258 | (1) |
|
Effects of other agents on EEG |
|
|
259 | (2) |
|
Key facts of anesthetic and proconvulsant effects of ketamine on EEG |
|
|
261 | (1) |
|
|
261 | (1) |
|
|
261 | (4) |
|
24 Electroencephalography and anesthetic doses of ketamine |
|
|
|
|
|
|
265 | (1) |
|
|
265 | (5) |
|
|
267 | (1) |
|
Neurophysiological underpinnings of the EEG effects of ketamine |
|
|
268 | (1) |
|
Interactions between ketamine and other hypnotic drugs |
|
|
269 | (1) |
|
Applications to other areas |
|
|
270 | (1) |
|
|
270 | (1) |
|
|
271 | (1) |
|
|
271 | (1) |
|
|
271 | (1) |
|
|
272 | (3) |
|
25 Linking heart function and analgesia |
|
|
|
|
|
|
|
|
275 | (1) |
|
|
276 | (6) |
|
|
276 | (1) |
|
|
277 | (5) |
|
|
282 | (1) |
|
Application to other areas: Effects of NSAIDs on the kidney |
|
|
282 | (1) |
|
Other agents of interest: Adjuvants |
|
|
282 | (1) |
|
|
283 | (1) |
|
|
284 | (1) |
|
|
284 | (3) |
|
26 Computed tomography-guided procedures for epidural injections |
|
|
|
|
|
|
287 | (1) |
|
General principles and technique common to all types of CT-guided epidural injections |
|
|
287 | (2) |
|
|
287 | (1) |
|
Three phases of CT-guided interventions |
|
|
287 | (2) |
|
|
289 | (5) |
|
Interlaminar epidural injections |
|
|
290 | (1) |
|
Cervical transforaminal epidural steroid injections |
|
|
290 | (1) |
|
Thoracic transforaminal epidural steroid injections |
|
|
291 | (1) |
|
Lumbar transforaminal steroid injections |
|
|
292 | (2) |
|
|
294 | (1) |
|
|
294 | (1) |
|
|
295 | (1) |
|
Applications to other areas |
|
|
295 | (1) |
|
|
295 | (1) |
|
|
296 | (1) |
|
|
296 | (1) |
|
|
296 | (1) |
|
|
296 | (3) |
|
27 Chronic pain: Linking deep brain stimulation and sensory functional MRI |
|
|
|
|
|
|
299 | (1) |
|
History of deep brain stimulation for chronic pain |
|
|
299 | (1) |
|
|
300 | (1) |
|
Modern visualization of DBS targets |
|
|
301 | (1) |
|
Application to other areas |
|
|
302 | (1) |
|
Other methods of interest |
|
|
302 | (1) |
|
|
303 | (1) |
|
|
303 | (1) |
|
Key facts of deep brain stimulation |
|
|
303 | (1) |
|
Key facts of sensory functional MRI |
|
|
303 | (1) |
|
Key facts of diffusion tensor imaging (DTI) |
|
|
304 | (1) |
|
|
304 | (1) |
|
|
304 | (3) |
|
28 Neurocognition and placebo analgesia: Linking in functional magnetic resonance imaging |
|
|
|
|
|
307 | (1) |
|
Understanding the placebo effect: From the biological approach to the advent of neuroimaging techniques |
|
|
308 | (1) |
|
Pain modulatory mechanisms relevant for the neuroimaging study of PA |
|
|
309 | (1) |
|
Pain and nociceptive stimuli in neuroimaging study of PA |
|
|
309 | (1) |
|
Pain evaluation and temporal phases in neuroimaging study of PA |
|
|
310 | (1) |
|
Sample characteristic relevant for the neuroimaging study of PA |
|
|
310 | (1) |
|
Neurocognitive predictors in neuroimaging study of PA: Attention, expectation, and reappraisal |
|
|
311 | (1) |
|
The neuroimaging meta-analytic approach to the study of PA and related neurocognitive factors |
|
|
312 | (1) |
|
Neuroimaging findings in the study of PA in Alzheimer's disease |
|
|
313 | (1) |
|
|
313 | (1) |
|
Applications to other areas |
|
|
313 | (1) |
|
|
314 | (1) |
|
|
314 | (1) |
|
Key facts of functional magnetic resonance imaging |
|
|
314 | (1) |
|
|
315 | (1) |
|
|
315 | (5) |
|
29 Linking the cortex, functional spectroscopy, and pain: Features and applications |
|
|
|
|
|
Jairo Alberto Dussan-Sarria |
|
|
|
320 | (1) |
|
Cortical functions related to pain processing |
|
|
320 | (1) |
|
Role of the motor cortex in pain processing |
|
|
321 | (1) |
|
Role of the PFC in pain processing |
|
|
322 | (1) |
|
Nature of brain region's recruited during pain: Insights from human imaging studies |
|
|
322 | (1) |
|
The biological rationale behind near-infrared spectroscopy |
|
|
322 | (1) |
|
fNIRS neuroimaging: Technical aspects, advantages, limitations, and applications |
|
|
323 | (3) |
|
The sequence of steps to perform neuroscience studies using fNIRS |
|
|
326 | (1) |
|
Dynamic trace pattern evoked by electrical stimulation |
|
|
327 | (1) |
|
Applications of fNIRS in pain research |
|
|
327 | (3) |
|
fNIRS and cortical connectivity in pain research |
|
|
330 | (1) |
|
Remarks and future directions |
|
|
331 | (1) |
|
Applications to other areas |
|
|
331 | (1) |
|
|
332 | (1) |
|
Key factors related to fNIRS |
|
|
332 | (1) |
|
|
332 | (1) |
|
|
333 | (4) |
|
30 Muscle origins of myofascial pain syndrome |
|
|
|
Eva Maria Martinez-Jimenez |
|
|
|
|
|
Marta Elena Losa-Iglesias |
|
|
|
|
Ricardo Becerro-de-Bengoa-Vallejo |
|
|
|
|
337 | (1) |
|
Nociception in muscle tissue |
|
|
338 | (1) |
|
Referred pain and peripheral sensitization process |
|
|
339 | (1) |
|
Sympathetic facilitation of muscle pain |
|
|
339 | (1) |
|
|
339 | (3) |
|
|
342 | (1) |
|
|
342 | (1) |
|
Application to other areas |
|
|
342 | (1) |
|
|
342 | (1) |
|
|
342 | (1) |
|
Key facts of myofascial pain |
|
|
343 | (1) |
|
|
343 | (1) |
|
|
343 | (6) |
Part III Psychology and behavior |
|
|
31 Behavioral markers of pain: Understanding the cognitive, motor, and societal interactions in the pain experience |
|
|
|
|
|
|
|
349 | (2) |
|
|
349 | (1) |
|
|
349 | (1) |
|
|
350 | (1) |
|
Comorbidities and chronic pain |
|
|
350 | (1) |
|
|
351 | (1) |
|
|
351 | (1) |
|
Changing our motor behaviors |
|
|
351 | (1) |
|
Social interactions and pain behavior convention |
|
|
352 | (2) |
|
|
352 | (1) |
|
Community structure-Access to resources |
|
|
353 | (1) |
|
Biological sex and gender |
|
|
353 | (1) |
|
What is coming in the next 5-10 years? |
|
|
354 | (1) |
|
|
354 | (1) |
|
Application to other areas |
|
|
355 | (1) |
|
|
355 | (1) |
|
|
355 | (1) |
|
|
355 | (1) |
|
|
356 | (1) |
|
|
356 | (3) |
|
32 Adverse life events, sensitization of spinal nociception, and chronic pain risk |
|
|
|
|
|
Adverse life events: A definition |
|
|
359 | (1) |
|
Adverse life events and health |
|
|
359 | (1) |
|
Adverse life events and chronic pain |
|
|
359 | (1) |
|
The impact of adversity (stress) on nociception in animals |
|
|
360 | (1) |
|
Pain systems and their assessment in humans |
|
|
360 | (1) |
|
Adversity and pain processing in humans |
|
|
361 | (7) |
|
Adversity, latent sensitization, and pain risk |
|
|
368 | (1) |
|
Implications and future directions |
|
|
369 | (1) |
|
|
370 | (1) |
|
Applications to other areas |
|
|
371 | (1) |
|
|
371 | (1) |
|
|
371 | (1) |
|
Key facts about adversity |
|
|
371 | (1) |
|
|
371 | (1) |
|
|
372 | (1) |
|
|
372 | (3) |
|
33 Cognitive-affective modulation of pain: The placebo and nocebo phenomena and their impact on pain treatment |
|
|
|
|
|
|
|
375 | (1) |
|
Psychological mechanisms of placebo analgesia and nocebo hyperalgesia |
|
|
376 | (1) |
|
Neurobiological and neurochemical mechanisms of placebo analgesia and nocebo hyperalgesia |
|
|
377 | (3) |
|
The relevance of placebo and nocebo effects for pain treatment in clinical practice |
|
|
380 | (2) |
|
Applications to other areas |
|
|
382 | (1) |
|
Placebo and nocebo phenomena related to nonopioid drugs and implications for pain treatment |
|
|
382 | (1) |
|
|
382 | (1) |
|
Role of cognitive behavioral therapy in placebo/nocebo and pain treatment |
|
|
382 | (1) |
|
|
383 | (1) |
|
Key facts of placebo analgesia |
|
|
383 | (1) |
|
Key facts of nocebo hyperalgesia |
|
|
384 | (1) |
|
|
384 | (1) |
|
|
385 | (2) |
|
34 Nociception-related behavioral phenotypes in adult zebrafish |
|
|
|
|
|
|
|
|
387 | (1) |
|
Nociception and pain in animal models |
|
|
387 | (1) |
|
Zebrafish as animal model for translational pain research |
|
|
388 | (1) |
|
Zebrafish-based pain models |
|
|
389 | (1) |
|
Applications to other areas |
|
|
390 | (1) |
|
|
390 | (1) |
|
|
391 | (1) |
|
|
391 | (1) |
|
|
391 | (1) |
|
|
391 | (1) |
|
|
391 | (4) |
|
35 Pain, implantable pain devices, and psychosocial aspects of pain |
|
|
|
|
|
|
|
|
395 | (1) |
|
Psychosocial aspects of neuropathic pain |
|
|
396 | (1) |
|
Rationale for psychosocial evaluations |
|
|
397 | (1) |
|
Effect of spinal cord stimulation on pain processing |
|
|
398 | (1) |
|
Effects of modes of stimulation on psychosocial aspects of pain |
|
|
399 | (1) |
|
|
400 | (1) |
|
Application to other areas |
|
|
401 | (1) |
|
|
401 | (1) |
|
|
401 | (1) |
|
Key facts of pain, implantable devices, and psychosocial aspects of pain |
|
|
401 | (1) |
|
|
402 | (1) |
|
|
402 | (3) |
|
36 Influence of psychological factors on myofascial pain |
|
|
|
|
|
Ricardo Becerro-de-Bengoa-Vallejo |
|
|
Marta Elena Losa-Iglesias |
|
|
|
|
|
Eva Maria Martinez-Jimenez |
|
|
|
|
405 | (7) |
|
Myofascial trigger point types |
|
|
405 | (1) |
|
Relationship between psychological factors and myofascial pain |
|
|
406 | (1) |
|
Personality traits and myofascial pain |
|
|
406 | (2) |
|
Anxiety and myofascial pain |
|
|
408 | (1) |
|
Depression and myofascial pain |
|
|
409 | (1) |
|
Catastrophism and myofascial pain |
|
|
409 | (1) |
|
Pain fear-avoidance and kinesiophobia and myofascial pain |
|
|
410 | (1) |
|
Central sensitization and myofascial pain |
|
|
411 | (1) |
|
|
411 | (1) |
|
Application to other areas |
|
|
412 | (1) |
|
|
412 | (1) |
|
|
412 | (1) |
|
Key facts of myofascial pain |
|
|
412 | (1) |
|
|
412 | (1) |
|
|
412 | (7) |
Part IV Resources |
|
|
37 Recommended resources, sites, and research groups for the neuroscience of anesthetics and analgesics |
|
|
|
|
|
|
|
419 | (1) |
|
|
420 | (1) |
|
Applications to other areas |
|
|
420 | (4) |
|
|
424 | (1) |
|
|
425 | (1) |
|
|
425 | (1) |
|
|
425 | (1) |
|
|
426 | (1) |
Index |
|
427 | |